Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed Quote. Delayed London Stock Exchange - 09/24 11:35:14 am
8845 GBX   +2.04%
01:15pHealth Care Stocks Retreat Friday
MT
12:19pEurostoxx 50 : European stocks slip on Evergrande woes, weak German business morale
RE
11:21aEuropean ADRs Move Lower in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thai hospital tycoon sticks to guns on vaccine claims

07/16/2021 | 06:22am EDT
Boon Vanasin, Chairman of Thonburi Healthcare Group, gives interview in Bangkok

BANGKOK (Reuters) - Thailand's Thonburi Healthcare Group Pcl (THG) doubled down on its outspoken chairman's claim to be buying Pfizer-BioNTech vaccines on Friday, helping its share price rise despite denials by both drugmakers.

Dr. Boon Vanasin's claim that his group, a more than $800 million private medicine empire, was close to signing a deal for 20 million Pfizer-BioNTech coronavirus vaccines to import to Thailand was swiftly denied on Thursday by both companies, one day after a government agency filed a defamation suit against Boon, 82.

On Friday, THG stuck to its guns.

"THG has agreed to buy the vaccine and is currently in the process of filing documents with overseas dealers," the company said in a statement.

Boon even told local media an agreement would be signed by Friday afternoon. By close of business, there was still no evidence of any deal.

THG shares closed 1.59% higher, having been up as much as 4% at one point.

It's still unclear whether Boon was insincere, the victim of a scam or - as he asserts - in the process of a brilliant fix to Thailand's desperate vaccine needs.

Boon insists a deal was in the works through a government agency, which he declined to name.

"We are not doing it directly," he told Reuters.

Still, his comments on Thursday added about 1.5 billion baht ($45.80 million) to THG's market capitalisation, bring it to 26.8 billion baht ($818.32 million), Refinitiv Eikon data shows.

Thailand so far has only vaccinated 5 percent of its population of more than 66 million. It has been administering China's Sinovac vaccine and the AstraZeneca's shots but the government seeking other imported doses.

Boon, the Thai word for merit, has been on a quest for COVID-19 vaccines for months, arguing that the government should not monopolise supply and calling the vaccine policy "complacent and reckless."

In February, he tried to import vaccines, but was unsuccessful and later lodged a protest..

Months later state drugmaker, the Government Pharmaceutical Organization (GPO), said it would import five million doses of Moderna vaccine for private hospitals.

Demand for mRNA vaccines in Thailand is growing. Pre-orders for Moderna vaccines through private hospitals were snapped up in a hurry.

Boon criticised the GPO for its process and on Wednesday the GPO slapped a defamation suit against the John Hopkins-trained physician. He said he welcomed the complaint because evidence and documents could be revealed in court.

Boon founded Thonburi hospital in 1976 and oversaw its expansion into a network of seven hospitals with 963 registered beds. He took the company public in 2017.

THG, which also operates hospitals in Cambodia and Myanmar, booked losses of 215 million baht in the first quarter this year, taking a hit from the pandemic and drop off in medical tourists.

The group is smaller than rivals like Bangkok Dusit Medical Services Pcl, and before the pandemic, its chairman began to carve out a niche. In 2017, he launched a $500 million 'medical city' for the elderly called Jin Wellbeing County, targeting Thailand's ageing population and foreign retirees.

($1 = 32.7500 baht)

(Reporting by Chayut Setboonsarng; Editing by Simon Cameron-Moore)

By Chayut Setboonsarng


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 2.04% 8845 Delayed Quote.18.35%
BANGKOK DUSIT MEDICAL SERVICES PUBLIC COMPANY LIMITED 0.00% 22.9 End-of-day quote.10.10%
MODERNA, INC. -5.38% 430.14 Delayed Quote.311.74%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
THONBURI HEALTHCARE GROUP PUBLIC COMPANY LIMITED 0.77% 32.75 End-of-day quote.27.18%
All news about ASTRAZENECA PLC
01:15pHealth Care Stocks Retreat Friday
MT
12:19pEurostoxx 50 : European stocks slip on Evergrande woes, weak German business morale
RE
11:21aEuropean ADRs Move Lower in Friday Trading
MT
10:06aASTRAZENECA : Receives a Buy rating from Barclays
MD
09:21aWall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09:15aHealth Care Stocks Slip Pre-Bell Friday
MT
08:59aIMPERIAL COLLEGE LONDON : Imperial RNA technology to be developed by VaxEquity with AstraZ..
AQ
08:26aDEPARTMENT OF HEALTH AND SOCIAL CARE : check the rules for travel to England from abroad
AQ
07:35aASTRAZENECA : Lynparza in combination with abiraterone significantly delayed disease progr..
AQ
06:46aASTRAZENECA : LYNPARZA« (olaparib) in combination with abiraterone significantly delayed d..
BU
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 33,8x
Yield 2021 2,33%
Capitalization 187 B 187 B -
EV / Sales 2021 5,98x
EV / Sales 2022 4,85x
Nbr of Employees 76 100
Free-Float 96,3%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 120,91 $
Average target price 136,24 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC18.35%184 418
JOHNSON & JOHNSON4.75%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.51%210 490